阿斯利康股票因乳腺癌试验意外失败而暴跌

2026-09-11 · investors.com

阿斯利康股票在周五尾盘交易中暴跌，此前该公司实验性乳腺癌治疗药物未能通过检验。

Amgen, AstraZeneca Score With Tezspire; Can They Take On Dupixent?

8/27/2026 Amgen and AstraZeneca's drug, Tezspire, scored Thursday in an esophageal disease t...